Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof inventions 05/06

20060111551 - Peptide having htlv-1-specific ctl-inducing activity: The present invention provides a peptide having HTLV-I-specific CTL-inducing activity that can induce cytotoxic T cells (CTL) having anti-tumor effect to human T cell leukemia virus-I (HTLV-I) tumor such as adult T-cell leukemia (ATL); a vaccine to induce immune response by using these; a diagnostic agent to examine immune function...

20060111552 - Metal binding precursors for the synthesis of peptide-metal conjugates: Specific metal-chelating precursors incorporating a pendant protected (e.g. with Fmoc) amino acid functionality are synthesised. The pendant amino acid functionality allows the chelator to be inserted into a synthetic peptide sequence during standard solid-phase peptide synthesis at any predetermined position in the sequence, in place of lysine or any other...

20060111553 - Novel thrombin inhibitors, the preparation and use thereof: e

20060111554 - Method, computing routine, device for predicting properties of mhc/peptide complexes, and data and peptides produced therefrom: The present invention relates to a method for structure-based prediction of properties of peptides and peptide analogs in complex with major histocompatibility (MHC) class I and class II molecules. The said properties mainly relate to the three-dimensional structure of an MHC/peptide complex and the binding affinity of a peptide for...

20060111556 - Preventives/remedies for neurodegenerative diseases: A compound or its salts inhibiting the activity of the protein of the present invention, a compound inhibiting the expression of a gene for the protein, the antisense polynucleotide of the present invention, the antibody of the present invention, and the like can be used as prophylactic/therapeutic agents for neurodegenerative...

20060111555 - Protein crystallisation method: A method for the crystallization of macromolecules in a three-phase system using a vessel containing a lower aqueous phase, a middle phase and an upper hydrophobic phase having a lower density than that of the lower aqueous phase, wherein an aqueous solution of the macromolecules is added to the middle...

20060111558 - Recombinant infectious laryngotracheitis virus and uses thereof: The present invention provides a recombinant, attenuated infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the glycoprotein gG gene. This attenuated virus is useful as a vaccine against infectious laryngotracheitis virus. The present invention also provides a recombinant, attenuated infectious laryngotracheitis virus comprising the...

20060111557 - Water soluble toxin produced by pfiesteria species: An isolated and purified Pfiesteria toxin having the NMR spectra given in FIG. 1 herein is described. The toxin may be produced by (a) culturing a Pfiesteria species in a growth media to produce Pfiesteria toxin therein; (b) separating a first fraction of organic compounds including said Pfiesteria toxin from...

20060111559 - Human g-protein chemokine receptor (ccr5) hdgnr10: The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors,...

20060106196 - Antigenic peptides derived from telomerase: This invention relates to proteins or peptides that elicit T cell mediated immunity, and to cancer vaccines and compositions for anti-cancer treatment comprising such proteins or peptide fragments. This invention also relates to pharmaceutical compositions comprising the proteins or peptides and methods for generating T lymphocytes capable of recognizing and...

20060106197 - Intracellular delivery of small molecules, proteins, and nucleic acids: An amino acid sequence Arg-Lys-Met-Leu-Lys-Ser-Thr-Arg-Arg-Gln-Arg-Arg (SEQ ID NO:1) functions as a protein transduction domain (PTD) and is capable of delivering small molecules, proteins, and nucleic acids to an intracellular compartment of a cell. An amino terminal lysine linker improves the efficiency of the PTD. A nuclear localization signal can be...

20060106198 - Antimicrobials against pathogenic bacteria and method for screening them: The present invention provides antimicrobials for efficient therapy of infections caused by bacterial pathogens. The antimicrobials include peptides corresponding to the active site of N-terminal extension of subunits composing specific adhesive organelles of virulence of pathogenic bacteria. These antimicrobial peptides inhibit surface expression of adhesive organelles and thus prevent development...

20060106201 - Novel hemopoietin receptor protein, nr12: A novel hemopoietin receptor gene (NR12) was successfully isolated by extracting motifs conserved among the amino acid sequences of known hemopoietin receptors and by using the predicted sequence. The NR12 gene encodes two forms of proteins, a transmembrane type and a soluble type. The expression of the NR12 gene was...

20060106202 - Peripheral-type benzodiazepine receptor associated proteins, cloning, expression and methods of use: The present invention relates to nucleic acids encoding PBR-associated proteins (PAPs) and methods for use in producing PAPs and methods of using PAPs. In this study we have identified proteins (PAPs) that interact with PBR protein by a yeast two-hybrid system. We used PBR as bait to screen a mouse...

20060106200 - Soluble, functional apoptotic protease-activating factor 1 fragments: The structure of a soluble, functional fragment of human Apaf-1 protein having ADP bound thereto is disclosed. The invention includes such soluble, functional fragments of human Apaf-1 and other metazoan Apaf-1 homologs. Also included in the invention are methods of making such fragments and methods of using them, for example...

20060106199 - Streptavidin-binding peptide: The invention relates to novel streptavidin binding peptides....

20060106203 - Ligand: The invention provides a dual-specific ligand comprising a first immunoglobulin variable domain having a first binding specificity and a complementary or non-complementary immunoglobulin variable domain having a second binding specificity....

20060106204 - Bifunctional energy-reversible acyl-compositions: Energy-reversible acyl conjugates, intermediates, and related compositions are disclosed. In preferred aspects, examples of such compositions include:...

20060106205 - Process for protein extraction: The invention includes a process for extracting a target protein from E. coli cells that includes lowering the pH of a whole E. coli cell solution to form an acidic solution, disrupting the cells to release the protein into the acidic solution, and separating the cellular debris from the released...

20060100415 - Process for purifying glycopeptide phosphonate derivatives: Disclosed are methods of purifying glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups that are useful as antibacterial agents. The methods include contacting a solution of the glycopeptide derivatives with a polystyrene-containing resin, eluting the resin with an aqueous solution, and isolating...

20060100418 - Cultured xenopus cell line expressing mutated apc: Using protein visualization techniques, cell lines stably expressing GFP-fused full-length and mutant APCs were obtained from cultured Xenopus laevis renal epithelial A6 cells. The use of these cells showed that mutant APCs, whose C-terminal region is absent, induced piling up of cells. Furthermore, piled up cells from mutant APC-expressing cell...

20060100417 - Isolated human transporter proteins nucleic acid molecules encoding human transporter proteins and uses thereof: The present invention provides amino acid sequences of peptides that are encoded by genes within the human genome, the transporter peptides of the present invention. The present invention specifically provides isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the transporter peptides, and methods of identifying...

20060100416 - Novel substitution mutant receptors and their use in an nuclear receptor-based inducible gene expression system: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a Group H nuclear receptor-based inducible gene expression system and methods of modulating the expression...

20060100419 - Prekallikrein depleted plasma derived albumin fraction: An albumin containing fraction having a reduced prekallikrein activator (PKA) content and a method of manufacturing same comprising the steps of: (a) reconstitution of paste V (Cohn fractionation), (b) performing a concentration step of the fraction obtained in step (a), (c) heating the fraction obtained in step (b) in a...

20060100420 - 5-hydroxytryptophol (5-htol) derivatives, antibodies, immunoassays and detection of recent alcohol consumption: Antibody specific for a 5-HTOL compound. A glucuronide with 5-hydroxytryptophol (5-HTOL) characterized in that it comprises the structure of the β-glucuronide between the 5-hydroxy group of 5-HTOL and D-glucopyranosiduronic acid. An immunoassay and a diagnostic method utilizing the immunoassay wherein a 5-hydroxytryptophol (5-HTOL) compound is determined by the use of...

20060094863 - Cat kidney disease marker: In view of the increase in the number of cases with nephropathy in aged animals of the cat family, the invention provides a marker for early diagnosis of feline nephropathy which can substitute for the conventional complicated methods of diagnosing nephropathy such as blood examination, kidney radiography using a contrast...

20060094862 - Specificity exchangers that redirect antibodies to a pathogen: Specificity exchangers and methods of making and using specificity exchangers are disclosed. Specificity exchangers are useful for preventing and treating human diseases including cancer and those resulting from pathogens such as bacteria, yeast, parasites, fungus, viruses, and the like. More specifically, specificity exchangers can redirect existing antibodies in a subject...

20060094864 - Pro16090 antibodies: The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides...

20060094865 - Intraoperative method for isolating and concentrating autologous growth factors and for forming residual autologous growth factor compositions: This invention is concerned with methods and devices for isolation or concentration of autologous growth factors; particularly autologous growth factors derived from blood or bone marrow or other bodily fluid/cell compositions in an intraoperative manner. Additionally, this invention provides specifically tailored growth factor residual compositions resulting from removal of one...